Market research
EYEN Eyenovia Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 81M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 1.0
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US30234E1047
- Market cap
- 81M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 1.0
About
About Eyenovia Inc
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EYEN discussion.
5 years, 4 months ago
Eyenovia, Inc is currently in a long term downtrend where the price is trading 9.5% below its 200 day moving average.
From a valuation standpoint, the stock is 95.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.1.
Eyenovia, Inc's total revenue sank by inf% to $-800M since the same quarter in the previous year.
Its net income has dropped by 377080.7% to $-20B since the same quarter in the previous year.
Finally, its free cash flow grew by 230.6% to $5M since the same quarter in the previous year.
Based on the above factors, Eyenovia, Inc gets an overall score of 2/5.